Nothing said here yet.
to join the conversation.
| Venker EricPresident & Immunovant CEO | Sell | 200,000 | $7.3M | Wed, Oct 28 |
| Venker EricPresident & Immunovant CEO | Sell | 185,856 | $6.5M | Tue, Oct 20 |
| Venker EricPresident & Immunovant CEO | Sell | 14,144 | $501.0K | Tue, Oct 20 |
| Epperly Melissa B,Director | Sell | 16,850 | $607.9K | Thu, Oct 1 |
| Epperly Melissa B,Director | Sell | 900 | $32.9K | Thu, Oct 1 |
| Venker EricPresident & Immunovant CEO | Sell | 200,000 | $7.3M | Wed, Sep 30 |
| Fitzgerald MeghanDirector | Sell | 4,712 | $187.0K | Tue, Sep 15 |
| Epperly Melissa B,Director | Sell | 4,338 | $172.0K | Tue, Sep 15 |
| Epperly Melissa B,Director | Sell | 600 | $24.2K | Tue, Sep 15 |
| Fitzgerald MeghanDirector | Sell | 400 | $16.2K | Tue, Sep 15 |
| Fitzgerald MeghanDirector | Sell | 20,000 | $798.0K | Tue, Sep 8 |
| Venker EricPresident & Immunovant CEO | Sell | 166,182 | $5.9M | Fri, Aug 28 |
Key TakeawaysRoivant shares jumped 8% today after brepocitinib met the main goal and every key secondary goal in two Phase 3 trials in non-infectious uveitis.
Roivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision…
Investing.com -- Roivant Sciences Ltd (NASDAQ:ROIV) shares jumped 9% in premarket trading Wednesday after the company announced brepocitinib met all Phase 3 endpoints in trials for non-infectious uveitis.
Roivant Sciences has delivered a very strong multi year share price run, which now puts a spotlight on whether the current market value lines up with what its balance sheet actually supports.
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program.